null
US
Entrar
Registre-se gratuitamente
Registre-se
Detectamos que o JavaScript não está habilitado no teu navegador. Habilite o Javascript para o funcionamento correto do nosso site. Por favor, leia os
Termos e Condições
para mais informações.
Próximo
Copiar e Editar
Você deve estar logado para concluir esta ação!
Inscreva-se gratuitamente
42077
Breast cancer - the role of the oncologist
Descrição
Cancer Biology Mapa Mental sobre Breast cancer - the role of the oncologist, criado por maisie_oj em 09-04-2013.
Sem etiquetas
cancer biology
cancer biology
Mapa Mental por
maisie_oj
, atualizado more than 1 year ago
Mais
Menos
Criado por
maisie_oj
mais de 11 anos atrás
113
1
0
Resumo de Recurso
Breast cancer - the role of the oncologist
Breast cancer
Incidence
In 2007 just over 25,000 cases in the age group 45-69yrs - (200-400 cases per 100,000 women)
Death rates now below 50 per 100,000 women
High risk group = 45-70yrs
Presentation
Breast lump/thickening, +/- axillary lymph node lump
Nipple retraction, nipple discharge
Skin changes: redness, oedema or dimpling
Diagnosis
Triple assessment
Clinical; history and examination
Imaging; mammogram, ultrasound,
Pathology; core biopsy and fine needle aspirate
Analysis of the biopsies
Microscopy
Cell morphology
Tissue morphology (ductal or lobular)
80% are invasive ductal
20% are invasive lobular
Tumour properties
Oestrogen receptor (ER) status
Nuclear stain for ER
Graded by H-score (0-300): % of cells stained multiplied by... 0 (negative); 1 (weak staining), 2 (moderate staining), 3 (strong staining)
HER2 (ErbB2) - epidermal GF receptor
By immunohistochemistry
Membrane stain
Graded as... (Based on intensity of stain and number of cells)
0 = negative
1 = negative
2 = borderline
Requires FISH
Using fluorescent DNA probes to detect the amplification of the HER2 gene
3 = positive
Prognosis Information
Grade - based on microscopic/clinical presentation
Tumour size
Nodal status
Spread to lymph nodes
ER, PR (progesterone receptor), HER2 status
Lymphovascular invasion
Invasion of the tissue blood/lymphatic vessels - typically precedes node involvement
Age
Nottingham prognostic index (NPI) - empirical method of calculating an individual's outcome
NPI = (0.2 x tumour size, cm) + tumour grade (1-3) + lymph node stage (1-3)
Good = <3
5/10/15yr survival rates = 96/86/80%
Intermediate = 4.51-5
5/10/15yr survival rates = 70/47/37%
Poor = >6
2/5/10yr survival rates = 67/32/21%
TNM staging
Tumour
T1 (<2cm); T2 (2-5cm); T3 (>5cm) and T4 (locally advanced - skin/chest wall involvement)
Node
N0 (no odes); N1 (mobile ipsilateral nodes); N2 (fixed ipsilateral nodes) and N3 (internal mammary nodes)
Metastases
M0 (no metastases) or M1 (distant metastases)
Treatment
Extent of disease
Localised
Operable?
Breast conserving surgery + Usentinel lymph node biopsy (SLNB) / axillary node clearance (ANC)
Mastectomy + SLNB/ANC
Offered with plastic surgery
Typically in combination with adjuvant therapy - eliminate micrometastases
Adjuvant therapy
Clinical trials reveal a combination of adjuvant therapies to reduce risk of patient mortality by 50-65%
However absolute patient benefit depends on patient risk group
Non-operable (too big/complicated?)
Neoadjuvant/primary systemic treatment
Attempt to shrink the tumour with adjuvant therapy to allow surgery
Metastatic
Palliative treatment
Chemo - faster (10 months) and more effective response, more toxic
Endocrine - slower (2yrs) and less effective response, less toxic
Median survival = 2.5yrs
Common sites: lungs, liver, bone, brain, lymph nodes
Endocrine resistance
Develops over time by a mechanism not fully understood
Not absolute (end of treatment options) - response still possible with other drugs
everolimus - mTOR inhibitor (inhibits ER phosphorylation)
BOLERO 2 trial - combination of exemestane (aromatase inhibitor) and everolimus increases patient survival and progression-free survival (PFS)
lapatinib (HER2/EGFR RTK inhibitor) - in combination (e.g. with capecitabine)
EGF100151 trial
T-DM1 (antibody-drug conjugation) - Trastuzumab (herceptin0 is bound to DM1 (a microtubule inhibitor/cytotoxin) to deliver DM1 to HER2+ cells
EMILIA study
Revealed T-DM1 provides a PFS 3.2 month longer than lapatinib+capecitabine combination
Pertuzumab (HER2 dimerisation inhibitor - MAb)
CLEOPATRA trial (pertuzumab + trastuzumab + docetaxel)
Bevacizumab [avastin] (MAb to VEGFR - anti-angiogenesis)
E2100 trial (avastin+paclitaxel (mitosis inhibitor))
Johnston, 2010
Describes the cross talk between the ERE and GF signalling pathways
ER can still be activated by phosphorylation through GF (e.g. IGFR or HER2)- signalling pathways
Adjuvant therapies
Chemotherapy
Reduced risk of death = 20-35%
Numerous treatment regimens
CMF (cyclophasphamide, methotrexate, 5-fluorouracil)
Cyclophosphamide = alkylating agent (DNA damage)
Methotrexate = folate metabolism inhibitor (reduced nucleotide synthesis)
5-FU = Thymidylate synthase inhibitor (reduced nucleotide synthesis)
Anthracycline-containing regimens
FEC (5-FU, epirubicin, cyclophosphamide)
Epirubicin = intercolates with DNA
E-CMF (Epirubicin with standard CMF)
Normally used after surgery and radiotherapy
Taxane-containing regimen
FEC with docetaxel
Docetaxel = anti-mitotic drug
TAC (docetaxel [taxotere], doxyrubicin [adriamycin], cyclophosphamide)
Doxyrubicin = inhibits topoisomerase 2 (Inhibition of DNA replication and RNA synthesis)
Other agents...
Capecitabine = pro-drug of 5-FU
Gemcitabine = nucleotide analogue
Vinorelbine = mitosis inhibitor
Carboplatin = cisplatin analogue (DNA damage)
Eribulin = mitosis inhibitor (used after two previous chemo therapies)
Side effects
Acute
Immunosupression, nausea, diarrhoea, vomiting, hair loss, peripheral neuropathy and generally feeling shitty
Medium
Fatigue, menopausal symptoms and infertility
Late
Leukaemia and heart failure
Radiotherapy
Following all breast-conserving surgery
Maybe necessary after mastectomy
Local control of tumour
Reduces risk of recurrance ( following surgery alone)
Endocrine therapy
Only if ER and/or PR positive
= 70% of all breast cancers
Oestrogen signalling pathway (top = classical/genomic; mid = non-genomic/non-ligand dependant; bottom = ligand-dependant)
Ligand binds to cytosolic ER causing activation -> ER dimerise and bind to DNA at the response elements ERE's -> recruit Co-activators (CoA) and HATs
Activated ER can also bind to AP-1 (c-fos:c-jun TF)
GF signalling results in the phosphorylation of ER by Erk (MAPK) and Akt -> formation of transcription complex
Ligand binding can also recruit a cytosolic protein complex (including PI3K and Src) that activate Akt and cause transcription
History of treatment: 1896 - oophorectomy in breast cancer patient improved the outcome (patient survived 4 years)
Link between the ovaries and breast cell proliferation (hormones)
Premenopausal
Tamoxifen (for 5yrs)
Oestrogen analogue that inhibits ER dimer activation
Originally designed as a contraceptive
Classed as a selective oestrogen receptor modulator (SERM)
Clinical trials revealed benefit in patient survival from breast cancer (1980's)
Except in bone - where it acts as an agonist and promotes bone synthesis (preventing oesteoporosis - seen with aromatase inhibitors)
Also a partial-agonist in endometrial tissue - risk of endometrial cancer
Ovarian ablation (surgical removal [oophorectomy] or hormonal therapy e.g. zoladex [GnRH analogue])
Anti-oestrogen (e.g. faslodex)
Postmenopausal
Tamoxifen (low risk patients - for 5yrs)
Aromatase inhibitors (steroidal - exemestane; or non-steroidal - arimidex) for 5yrs
Inhibit oestrogen synthesis
Cause osteoporosis
Anti-oestrogen (e.g. faslodex)
Two trials
EBCTCG (Lancet, 2005)
Tamoxifen alone reduces chance of tumour recurrance by ~12% over 15yrs
Tamoxifen alone increases 15yr survival rate by 9.2%
ATAC (arimidex, tamoxifen; alone or combined) trial (Lancet oncology, 2008)
Reduced tumour recurrence and increased time until recurrence seen with arimidex over tamoxifen - in postmenopausal women (drug of choice)
Side effects
Tamoxifen
May induce menopause (hot flushes etc.)
Risk of venous thromboembolism (VTE)
Risk of endometrial cancer
Aromatase inhibitors
May induce menopause
Joint pains (~20% of cases)
Osteoporosis
Biological therapy
HER2 blockade
Amplified/overexpressed in 20-35% of breast cancers - associated with poor prognosis
No natural ligand and forms heterodimer when activated (e.g. with EGFR)
Many downstream substrates - including Ras signalling / Akt activation
Trastuzmab (Herceptin)
MAb - binds to the receptor and prevents dimerisation
Inhibits HER2 signalling
MAb signals for cell death by immune effector cells (e.g. NK cells)
MAb induces cell internalisation and degradation
4 trials (in >10,000 women)
HERA, NSAPB-31, N9831 and BCIRG006
BCIRG006 (NE J Med, 2011)
Patient survival was increased to >80% in patients recieving standard TAC regimen in combination with herceptin; compared to TAC alone (=75%)
Interim trials stopped early because of the obvious benefits; decreased relapse risk (-50%) and survival advantage of 2.5%
Anti-angiogenesis (clinical trials only at this point)
Avastin (bevcizumab)
Future
Mapping genes and understanding the genetic pathway of breast cancer will allow for a more tailored treatment that is more effective and less toxic
Personalised treatment regimens based on tumours genetic profile
Only 10% of breast cancers linked with an inherited mutation (e.g. BRCA1, BRCA2 - other minor risk genes = CHEK2, BRIP, PALB2 and ATM)
High risk families....
4 or more relatives with breast/ovary cancer
3 relatives <60yrs with breast/ovary cancer
2 relatives <40yrs with breast/ovary cancer
1 relative with both OR bilateral breast cancer
Quer criar seus próprios
Mapas Mentais
gratuitos
com a GoConqr?
Saiba mais
.
Semelhante
Principles of Chemotherapy
maisie_oj
10 Hallmarks of Cancer
callumhall64
Cancer and metabolism, pt.2
maisie_oj
Gene therapy application for cancer: virotherapy
maisie_oj
Cancer diagnosis: is it a tumour?
maisie_oj
Turning cancer targets into treatments
maisie_oj
PROTO-ONCOGENES
salu624
TUMOR SUPPRESSORS
salu624
Simulado Biologia
Marina Faria
Direito Constitucional Esquematizado - Pedro Lenza - Capítulo 2 - Exercícios
Anaximandro Martins Leão
Investigação científica
Claudina Quintino
Explore a Biblioteca